PLANO, TX & BALTIMORE, MD, USA I March 25, 2025 I Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

PARIS, France I March 25, 2025 I The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to ...